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Background: Children with cerebral palsy (CP) whom are non-ambulant are at risk of reduced quality of life and
poor health status. Severe spasticity leads to discomfort and pain. Carer burden for families is significant. This study
aims to determine whether intramuscular injections of botulinum toxin A (BoNT-A) combined with a regime of
standard therapy has a positive effect on care and comfort for children with CP whom are non-ambulant (GMFCS
IV/V), compared with standard therapy alone (cycle I), and whether repeated injections with the same regime of
adjunctive therapy results in greater benefits compared with a single injecting episode (cycle II). The regime of
therapy will include serial casting, splinting and/or provision of orthoses, as indicated, combined with four sessions
of goal directed occupational therapy or physiotherapy.
Method/design: This study is a double blind randomized controlled trial. Forty participants will be recruited. In
cycle I, participants will be randomized to either a treatment group who will receive BoNT-A injections into selected
upper and/or lower limb muscles, or a control group who will undergo sham injections. Both groups will receive
occupational therapy and /or physiotherapy following injections. Groups will be assessed at baseline then
compared at 4 and 16 weeks following injections or sham control. Parents, treating clinicians and assessors will be
masked to group allocation. In cycle II, all participants will undergo intramuscular BoNT-A injections to selected
upper and/or lower limb muscles, followed by therapy.
The primary outcome measure will be change in parent ratings in identified areas of concern for their child’s care
and comfort, using the Canadian Occupational Performance Measure (COPM). Secondary measures will include the
Care and Comfort Hypertonicity Scale (ease of care), the Cerebral Palsy Quality of Life Questionnaire (CP QoL–Child)
(quality of life), the Caregiver Priorities and Child Health Index of Life with Disabilities Questionnaire (CPCHILD©)
(health status) and the Paediatric Pain Profile (PPP) (pain). Adverse events will be carefully monitored by a clinician
masked to group allocation.
Discussion: This paper outlines the theoretical basis, study hypotheses and outcome measures for a trial of BoNT-A
injections and therapy for children with non-ambulant CP.
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Cerebral palsy (CP) is “a group of permanent disorders of
the development of movement and posture, causing activ-
ity limitation, that are attributed to non-progressive distur-
bances that occurred in the developing fetal or infant
brain”.[1] p.9 Classification systems have been developed
to indicate the severity of functional limitations in CP.
The Gross Motor Function Classification System
(GMFCS), developed by Palisano and colleagues in 1997,
has become internationally accepted for the classification
of gross motor abilities for children with CP [2]. The
GMFCS is comprised of 5 levels, with GMFCS I reflecting
the highest level of gross motor function. Children who
are classified GMFCS IV and V are the most functionally
impaired. Children classified as GMFCS IV require sup-
portive seating for trunk control and to maximize upper
limb function, and assistance for transfers. Self-mobility is
limited to possible use of a powered wheelchair. Children
who are classified as GMFCS V are unable to sit without
support and have difficulty maintaining antigravity head
and neck control. Children classified as GMFCS IV and V
comprise approximately one third of children with CP in
Australia [3].
The most common motor type of CP is the spastic
type [3]. Spasticity is “a velocity-dependent resistance of
a muscle to stretch”. [4] p.91 Spasticity commonly leads
to muscle contractures and eventual bony deformities,
which may result in decreased functional ability as a
child’s development progresses [5,6]. Children whose CP
is classified GMFCS IV or V frequently suffer from pain
[7-9]. Pain is often associated with marked spasticity,
spasms, skin breakdown, or postural positioning leading
to an increased burden of care. Even simple tasks like
dressing can become problematic when children have
high levels of spasticity [10]. Pain negatively impacts
children’s quality of life [9] and participation in school-
ing and family activities [8]. Pain is associated with a
higher risk of stress for parents of children with CP [11].
Pain, discomfort and carer burden lead parents to seek
treatments to reduce their child’s spasticity.
Spasticity can be reduced with intramuscular injec-
tions of botulinum toxin A (BoNT-A) [12]. When
injected into a target muscle, BoNT-A enters the pre-
synaptic terminal, and prevents the exocytosis of acetyl-
choline, thus reducing spasticity. The clinical effects
have been reported to last for approximately 3-6 months.
Intramuscular injections of BoNT-A, using BotoxW
(Allergan PLC) have been approved (March 2011) by theTherapeutic Goods Association Australia for treatment
of focal spasticity in the upper and lower limbs, includ-
ing dynamic equinus foot deformity, in children with ju-
venile CP from the age of two years. DysportW is an
alternative preparation of BoNT-A which will not be
used in this study. Research has demonstrated the ability
of BoNT-A to improve function for children with CP
whom are ambulant [13-18]. When used with ambula-
tory children, BoNT-A is considered to be generally safe
with relatively few and minor complications [19].
There is limited evidence for using BoNT-A with chil-
dren with CP whom are non-ambulant (GMFCS IV and
V) to reduce pain and improve ease of care. A small
double-blinded, placebo controlled randomized trial
examined the use of BotoxW pre-operatively for pain man-
agement post hip adductor release surgery for children
with severe CP [20]. Compared with the placebo group,
children who received BotoxW required significantly less
pain relief, including morphine (p< 0.03) and combined
narcotic dose (p < 0.009) after the first 48 hours post op-
eratively. The study concluded that there is a role for
BoNT-A in reducing pain post-surgically and that it may
have further clinical applications with this population. A
more recent report detailed the outcomes of a clinical co-
hort of 26 children with CP, GMFCS V with spasticity and
pain in the hip region who had injections of BoNT-A
(n= 17 had DysportW, n = 9 had BotoxW) to improve com-
fort [21]. Pain was measured pre and post treatment by
parent report using the Paediatric Pain Profile [22]. All
children in the study had reduced pain at 3 months post
BoNT-A, with a significant overall reduction in pain
(p< 0.001). Although not formally measured, improved
sleep patterns, tolerance of seating and ease of care were
reported. Another small pre post study of children with
severe CP evaluated the effects of intramuscular BoNT-A
injections on parent-proxy ratings of pain [23]. The study
did not report GMFCS levels of the participants; however
13 of the 34 children had non-ambulant (quadriplegic)
CP. Twenty-one (62%) participants experienced pain re-
duction one month after BoNT-A injections, as measured
by a telephone survey with each child’s parent. There were
no obvious child-specific characteristics that separated
those who had pain reduction and those who experienced
persistent pain however this report suggested that BoNT-
A injections may have analgesic effects.
The pain-relieving potential of BoNT-A has been more
rigorously investigated in adults [24,25]. In a rando-
mized, double blinded placebo controlled trial, BoNT-A
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associated with spasticity in adults following stroke [24].
Similar results were reported following injections to the
pectoralis major muscle in an adult population suggest-
ing that upper limb injections of BoNT-A may provide
pain relief [25]. Further well designed studies are needed
to validate the efficacy of BoNT-A when used to reduce
pain, improve comfort and reduce burden of cares in
children with non-ambulant CP.
Following reports of systemic adverse events, [26]
there has been increasing focus on the safety of BoNT-A
when used with children with CP. A systematic review
which included 20 randomized clinical trials of BoNT-A
found a good safety profile when used short term, how-
ever called for more research into a possible association
between BoNT-A, seizures and death [27]. A review of
the efficacy and safety of pharmacological treatments for
spasticity in children and adolescents with CP reported
that BoNT-A was an effective and generally safe treat-
ment however warned that generalized weakness may
occur [28]. A retrospective review of 1,980 BoNT-A in-
jection episodes in 1,147 children ranging from GMFCS
I –V found a low incidence of systemic adverse events
[29]. Incontinence occurred in 1% of cases, and respira-
tory symptoms requiring hospitalization in 1.3%. Higher
GMFCS levels (IV,V) and higher doses of BoNT-A were
associated with increased incidence of adverse events,
leading the authors to recommend conservative dosing
for children classified GMFCS IV-V [29].
A meta-analysis of the safety of BoNT-A using a var-
iety of preparations included 37 randomized controlled
trials across a range of indications including participants
with dystonia, movement disorders, spasticity and CP,
urological and gastrointestinal disorders and for cos-
metic use [30]. Data from 2,361 subjects of whom 1,447
had received BoNT-A were reviewed. The incidence of
side effects was 25% in BoNT-A treated patients and
15% in the control group. Of the side-effects, only focal
muscle weakness and ptosis occurred more frequently in
the treatment group [30]. Another retrospective review
of 929 patient encounters from a large movement disor-
ders centre reviewed the safety profile of high dose (15-
25 units BotoxW per kilogram per episode) BoNT-A
across domains such as the aetiology of CP, motor pat-
tern, ambulatory potential and muscles injected [31].
The review found adverse effects were randomly distrib-
uted across the range of phenotypes and doses. A single
blind randomized controlled trial assigned 90 children
with bilateral spastic CP, primarily GMFCS IV and V, to
either three years of six monthly injections of BoNT-A
(maximum dose BotoxW 16 units/kg/body weight) com-
bined with wearing a hip abduction brace for 6 hours/
day, compared to standard therapy treatment (no brace
or BoNT-A). In this study, two children in the treatmentgroup died due to reasons thought not to be related to
the BoNT-A injections [32]. Including these two deaths,
there were 12 serious adverse events out of 204 injection
episodes (6%), including four episodes of respiratory in-
fection, three episodes of transient urinary incontinence,
two cases of bronchospasm during recovery from gen-
eral anaesthesia and one flu-like episode.
Data from these studies suggest that, when used in
trial conditions, BoNT-A is a relatively safe treatment
for children with severe CP but a small proportion of
children may be susceptible to adverse events.
Children with severe CP are at risk of significant
comorbidities. O’Flaherty and colleagues conducted an
audit of health status in children with CP prior to
BoNT-A injections [33]. The incidence of health issues
was reported according to GMFCS levels. In the month
prior to injections they reported an incidence of 64/178
(36%) of health related issues including respiratory infec-
tions and seizures in children classified GMFCS V who
were booked for BoNT-A injections (including those
whose injections were cancelled for any reason). Liptak
and colleagues performed a multicentre study investigat-
ing the health status of children with GMFCS V and
found those who used a feeding tube had the lowest
mental age, required the most health care resources and
medications, had the most respiratory problems and the
lowest global health scores [34]. The heterogeneity of
clinical phenotypes in CP needs to be considered in
assessing the efficacy and safety of BoNT-A.
Previous studies of BoNT-A with children with CP
have largely focused on children classified GMFCS I –
III [13-15,35-43]. In these studies, assessments of motor
function have been used to test the ability of BoNT-A to
bring about functional improvements. In this study with
children with CP who have limited voluntary movement,
improvements in motor function are not widely
expected and are not the focus of investigation. Children
with CP whom are non-ambulant rely on their parents
for performance of daily activities. Spasticity and con-
tracture, with associated discomfort and pain, contribute
to these tasks being difficult, time consuming and/or
stressful for parents. In our clinical BoNT-A injecting
program, parents of children with severe CP regularly
set goals for intervention around improving ease of care
(for example, parents may hope for it to be easier to get
their child’s arm through a sleeve, quicker to apply lower
limb orthoses, or easier to perform transfers), and im-
proving their child’s comfort (for example, that their
child will tolerate sitting in their wheelchair for longer
periods, require less pain medication or have fewer night
wakings due to discomfort). Efficacy will be determined
through measurement of changes in parental percep-
tions of the ease of carrying out daily cares for their
child, and their child’s comfort, pre and post treatment,
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(COPM) [44].
Clinically, we observe that reduction of spasticity,
improved comfort and easier performance of daily cares
has the potential to improve a child’s quality of life,
health status and pain. Secondary outcome measures will
investigate the impact of injections of BoNT-A and ther-
apy on these factors.
In clinical practice, children who undergo BoNT-A
injections typically have repeat injections once the effects
have worn off. The majority of studies of BoNT-A with
children with CP have investigated a single injection epi-
sode however several have examined the efficacy of
repeated injections. A study of 22 young children with
hemiplegia compared three 16 week cycles of BoNT-A
injections followed by occupational therapy, with occupa-
tional therapy alone. They found that the group who had
BoNT-A had reduced spasticity and improvements in the
performance scale of the COPM, compared to the therapy
only group. [35]. Another study of young children with
hemiplegia included 42 children who had either two
or three cycles of upper limb BoNT-A injections and
occupational therapy over a 30 month period [14].
First and second injections demonstrated significant
effect sizes for quality of movement, goal attainment
and functional skills improvement. The study con-
cluded that repeated upper limb injections of BoNT-
A are safe and effective for children with unilateral
CP receiving occupational therapy. A study of lower
limb BoNT-A included ambulant children with CP
who were separated into three groups: BoNT-A alone,
BoNT-A + casting and casting + placebo injection
[45]. Each group received three treatment cycles, with
the study finding that the groups who received
BoNT-A + casting and casting + placebo obtained
successive improvement in ankle kinematics, spasti-
city, range of motion and strength.
To date, no study has evaluated the efficacy and
safety of repeated injections of BoNT-A for children
with non-ambulant CP. Cycle II of this study will ad-
dress this gap through a second phase of treatments,
in which all children will receive BoNT-A injections
followed by a standard therapy regime, as per cycle I.
Outcome measurement and monitoring of safety out-
comes will be performed as per cycle I. This will en-
able testing of the efficacy of repeat injecting and the
ability to determine the safety of two episodes com-
pared to one episode of injecting.
Intramuscular BoNT-A is widely used clinically for chil-
dren with CP whom are non-ambulant [46,47]. Research
is urgently needed in order to establish efficacy of intra-
muscular BoNT-A in meeting child and family goals for
improving quality of life by reducing pain and improving
care and comfort. This study aims to evaluate the efficacyof BoNT-A, while closely monitoring safety in children
with CP whom are non-ambulant.Methods/design
Study design
A double blind randomized controlled trial with two
cycles will be conducted to evaluate the efficacy of intra-
muscular injections of BoNT-A into selected upper and/
or lower limb muscles, in 40 children with non-
ambulant CP aged 2 to 16 years.
The specific hypotheses to be tested are:-
Cycle I
1. Intramuscular injections of BoNT-A combined with
a regime of standard therapy will result in improved
parental ratings of performance and satisfaction in
areas of concern for their child’s comfort and ease of
care, as measured by the COPM, compared to
standard therapy alone.
2. Intramuscular injections of BoNT-A combined with
a regime of standard therapy will result in greater
reduction in pain compared to standard therapy
alone.
3. Intramuscular injections of BoNT-A combined with
a regime of standard therapy will result in greater
improvements in quality of life compared to
standard therapy alone.
4. Intramuscular injections of BoNT-A combined with
a regime of standard therapy will not result in an
increased likelihood of adverse events compared to
standard therapy alone.
Cycle II
1. Repeated BoNT-A injections will result in greater
overall improvements in pain, quality of life, burden
of care and individual family concerns for ease of
care and comfort, compared with a single episode of
BoNT-A.
2. Repeated BoNT-A injections will not increase the
likelihood of an adverse event in a population of
children with non-ambulant CP, compared with a
single episode of injections.
Assessments will be performed at baseline, 4 weeks
and 16 weeks following injections/sham in cycle I and
at 4 weeks and 16 weeks following injections in cycle
II. There will be two months between cycles, resulting
in a total study duration of ten months. The experi-
mental design and outcome measures are depicted in
Figure 1.
Experimental design    Outcome measures 
Randomization 
Eligible children: children with cerebral palsy GMFCS IV or V 
Aged 2-16 years. 
No BoNT-A injections in previous 6 months  
Family have goals for care/comfort 
Spasticity causes discomfort and/or increased 
burden of care 
Not eligible or 
not interested  
No further 
contact. 
Screening assessment (T1) 
Baseline:  (T2) (n=40) 
BoNT-A and therapy (n=20) Sham and therapy (n=20) 
4 week review (T3) 
16 week review (T4) 
COPM 
CCHQ 








  Baseline Measures, T2, T3, T4, T5,  
  T6
Cycle II: 6 month post initial 
injection/sham :BoNT A injection 
Cycle II: 4 week review (T5) 
Cycle II: 16 week review (T6) 
Figure 1 Flow chart of care and comfort study according to CONSORT guidelines. Key:- BoNT-A, Botulinum Toxin A. GMFCS, Gross Motor
Function Classification System. MACS, Manual Ability Classification System. T1-T6. Time-points 1-6. COPM, Canadian Occupational Performance
Measure. CPQOL-Child, CP Quality of Life – Child. CCHQ – Child Health Questionnaire. PPP – Paediatric Pain Profile.
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dren’s Health Services, at the Royal Children’s Hospital,
Brisbane (EC 00175) has granted approval for the study.
Study sample and recruitment
Children and youth will be recruited from across Queens-
land, Australia. Financial support for families from re-
gional areas will be made available to allow equity of
access to the program and a representative sample of chil-
dren from metropolitan, outer metropolitan and rural/re-
gional/remote areas. Children will be identified as
potential candidates for the study by their treating Paedia-
trician or Rehabilitation Specialist at routine attendance at
multidisciplinary clinics. A screening assessment will be
performed by the child’s treating Physician to determine
eligibility.Inclusion criteria
The study will include children and youth:
1. With a confirmed diagnosis of CP classified
functionally as GMFCS level IV or V;
2. Aged 2-16 years at study entry;
3. With goals primarily concerned with improving ease
of care and/or comfort;
4. With spasticity in the upper and/or lower limbs
causing discomfort and/or increased burden of care.
Exclusion criteria
1. Predominant ataxic or hypotonic motor type;
2. Previous severe adverse event following BoNT-A
injections;
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history of allergic reaction to BoNT-A;
4. BoNT-A injections or orthopaedic surgery occurring
within 6 months prior to commencement of the
study;
5. If changes to oral or other antispasticity treatment
(e.g. intrathecal baclofen, oral baclofen) occur within
two months of the commencement of the study,
entry will be delayed until treatment has been stable
for two months.
Sample size
Sample size calculations were primarily based on the
findings from a placebo controlled trial of the analgesic
effects of BoNT-A in a sample of 16 children with
marked CP [20]. In this study, the response within each
subject group was normally distributed with a standard
deviation of 0.56. The mean difference in pain scores be-
tween the experimental and control groups at follow-up
was 0.74. If the true difference in experimental and con-
trol means is 0.74, we will be able to reject the null hy-
pothesis that the population means of both groups are
equal with probability (power) .981. The type 1 error
associated with this test of this null hypothesis is 0.05.
We also examined a study of upper limb BoNT-A injec-
tions and occupational therapy, with a heterogeneous
sample of 72 subjects that included 28 (39%) children
with quadriplegic (CP) [13]. In this study, COPM out-
comes at 3 months post injection resulted in a SD= 1.6.
A difference of 2 points on the performance and satis-
faction scales of the COPM, 80% power and significance
level of 0.05 gives a sample size of 24 (12 in each group).
Based on these previous studies and factoring in a buffer
for drop-outs, we plan to recruit 20 participants to each
group (total sample 40 subjects).
For the secondary hypothesis of safety in our double
blind sham controlled trial with 20 subjects in each
group, we examined a recent single blind randomized
controlled trial of BoNT-A in children with bilateral CP
[32]. That study reported a 6 percent rate of serious ad-
verse events in the BoNT-A group (failure rate in con-
trols of 0.01). If the true failure rate in the experimental
group is 0.333 then we will be able to reject the null hy-
pothesis that the failure rates for experimental and con-
trol subjects are equal in probability (power) 0.797 with
a type I error of 5 percent using an uncorrected chi-
squared statistic.
Randomization
Children will be randomly allocated to the treatment or
control group. Randomization will be performed using
concealed allocation. Prior to randomization, participants
will be stratified according to primary goal areas (upper
limb or lower limb) in order to allow block randomizationwith the intention that similar numbers of children with
predominantly upper and lower limbs injected will be in
each arm of the study.
Study treatments
Muscles for injection with BoNT-A will be selected on
the basis of the parent’s/carer’s priorities for improving
ease of care and comfort, as well as musculoskeletal
examination of range of motion and spasticity, using
the Modified Tardieu Scale [48] and the Modified Ash-
worth Scale [49]. The BoNT-A dosing regime was
determined with reference to the European consensus
table for the use of BoNT-A with children with CP
[50], which suggests a safe range of 6-25 units/kg/body
weight with a total dose of 400-600 units of BotoxW.
These recommendations were modified slightly when
reviewed in 2009 [51] to 1-20 units/kg/body weight,
suggested maximum dose 400 units of BotoxW, with cau-
tion urged when planning doses for children with signifi-
cant co-morbidities. Injections will be guided by
localization with ultrasound [52] and/or muscle stimula-
tion [53]. Doses will be 0.5-4 units/kg/muscle group as
clinically indicated to maximum dose of 12 units/kg/
body weight (or 400 units maximum) of BotoxW. A sham
procedure was chosen for the control group rather than
placebo injections, so as to minimize pain and discom-
fort for the participants. All injections and sham proce-
dures will be performed on a day procedure unit with a
trained, experienced Physician and two Clinical Nurse
Consultants (CNCs) in attendance. An alternative Phys-
ician in the investigative team (not the child’s regular
Physician) will carry out the procedure, to ensure blind-
ing of the treating Physicians who will carry out the re-
view assessments. The injecting Physician will be
assisted by a CNC. A second CNC will monitor the child
during the procedure. Parents will read a book to their
child while the procedure is being carried out, to provide
distraction. A screen blocking the parent’s, child’s and
monitoring CNC’s view of the procedure will ensure that
they remain unaware of group allocation.
Sedation/pain management during BoNT-A injections
When children with non-ambulant CP have BoNT-A
injections at our centre, a brief general anaesthetic is
typically administered. The side-effects of general anaes-
thesia can be similar to those considered to be possible
side effects of BoNT-A, including respiratory complica-
tions. A study by Naidu et al (2010) reviewed 1980 epi-
sodes of BoNT-A treatment and found that while the
incidence of respiratory complications was low, there
was a relationship to functional severity (GMFCS level),
with increasing GFMCS levels associated with increased
likelihood of unplanned hospital admission due to re-
spiratory complications [29]. Most of the children in the
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complications may have resulted from the anaesthetic
procedure, leading the authors to suggest that for chil-
dren with non-ambulant CP, alternatives to mask anaes-
thesia should be considered.
In order to more accurately ascribe adverse effects to
BoNT-A, participants in this study will be given intrana-
sal fentanyl (1.5mcg/kg / 300mcg/ml solution) for pain
relief 10 minutes prior to the procedure, as an alterna-
tive to general anaesthesia. Fentanyl is a short acting
lipophilic opioid analgesic. Previous reports have docu-
mented the safety and effectiveness of intranasal fentanyl
in paediatric and adult patients for management of pain-
ful procedures such as burns dressings, [54,55] manage-
ment of acute pain such as fractures, [56,57] and
postoperative analgesia [58-60]. Local pain relief will be
achieved by the application of Eutectic Mixture of Local
Anaesthetic (EMLA) to marked sites one hour prior to
injections. All injection sites will be covered with adhe-
sive dressings and tincture of iodine to mask the injec-
tion site.
Sham procedure
Children will have EMLA topical anaesthetic cream ap-
plied to marked injection sites one hour prior to the
sham procedure. The administration of intranasal fen-
tanyl will be mimicked by the administration of an
equivalent amount of intranasal saline, 10 minutes prior
to the sham procedure. The procedure will be mimicked
with ultrasound and a blunt needle (not penetrating the
skin) to the sites selected for injection, by a Physician.
The purpose of this is to imitate true time and actions
of the actual procedure to assist with blinding. All sites
will be covered with adhesive dressings and tincture of
iodine, to mask the sham injection site.
Therapy protocols and delivery
There are a lack of clinical BoNT-A trials that provide
evidence for optimal adjunctive therapy with children
with CP whom are non-ambulant. Consistent with inter-
national consensus statement recommendations, all par-
ticipating children will receive a block of therapy
treatment commencing within two weeks following
BoNT-A or sham [19,61]. Therapy will be provided by
experienced occupational therapists and/or physiothera-
pists. Treatments will aim to address the concerns and
priorities identified by families at the initial screening
visit, typically the reduction of impairments and symp-
tom management to ease pain and discomfort. Therapy
regimes will be based on international consensus recom-
mendations [19,61,62] and will include practices such as:
serial casting to lengthen muscles and reduce contrac-
tures, [45,63-66] strengthening of injected muscles and
antagonists, [67] provision of stretching programs to beimplemented into the child’s daily routines, [68] provision
of splints/orthoses, [69] and/or targeted motor training. It
is recognized that children with non-ambulant CP will
have difficulties participating in movement based therapy.
Provision of strengthening activities and targeted motor
training in a hydrotherapy medium will be provided in
order to enable participation in therapy programs [70].
The therapy plan will be determined apriori at the screen-
ing clinic, prior to randomization. Treating therapists will
be masked to group allocation. Children in both groups
will receive the same dose of therapy, consisting of up to
two weeks of serial casting if clinically indicated, and four,
one hour therapy sessions.
Monitoring of safety and adverse events
A pre-admission medical check detailing comorbidities
and health status will be conducted by the assessing
Physician at entry and the injecting Physician. During
the procedure, a nurse who is masked to group alloca-
tion (VW) will collect a record of in-procedure adverse
events and observations. Subsequently, information
about adverse events will be collected via a standardized
questionnaire at the following time points: immediately
following the procedure, 2 weeks following procedure
(via phone call), and at the 4 week and 16 week review
appointments. All adverse events data will be reported
to one of the blinded study investigators (PE), who will
grade each event, according to the following grading sys-
tem which is consistent with the Common Terminology
Criteria for adverse events, version 4.0:
1. Mild – awareness of sign or symptom, observations
only, intervention not indicated.
2. Moderate – discomfort causing interference with
usual activity, minimal or local intervention
indicated.
3. Serious/severe – medically significant, requirement
for IV therapy, prolongation of procedure or
hospitalization requirement within three months of
intervention.
4. Sentinel – Death or disability with a temporal
relationship to procedure [71].
If a sentinel event occurs monitoring of patients and
cessation of program until external review will be
mandatory.
Adverse events will be additionally categorized accord-
ing to a graded probability rating scale which considers
the causality/relationship of the event to the interventions
in the procedure in addition to the following: comorbid-
ities, temporal relationship, history of medical events and
family history. The scale will rate events as definitely/
probably, possibly, or unlikely/un-related to the interven-
tion [71]. Serious adverse events with suspected causal
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ternal clinical pharmacologist and the Ethics Committee
within 72 hours. The external assessor/ clinical pharma-
cologist will review all adverse events every 16 weeks,
unmasked to group allocation.
Outcome measures and procedures
1. Classification of the sample:
The participants entered into the study will be
classified according to:
a) Gross Motor Function Classification System
(GMFCS)
The GMFCS classifies severity of CP in terms of
gross motor function [2]. A child is assigned one of
five levels to describe their ability in self-initiated
movements, with a focus on sitting and walking. The
GMFCS has good construct validity with the Gross
Motor Function Measure (r = -0.91) [72] and clinical
relevance [73]. Inter-rater reliability is reported to be
high [74]. All children in this study will be classified
GMFCS IV or V (non-ambulatory).
b) Manual Ability Classification System (MACS)
The MACS is a five-point scale corresponding to the
structure of the GMFCS, which classifies how a
child uses their hands to perform day-to-day
activities that are appropriate for their age [75].
Inter-rater reliability of the MACS is excellent as
reported by Eliasson et al., 2006 (ICC= 0.97 (0.96 –
0.98)) [75]. It is expected that most children in the
study will be MACS level V (does not handle
objects) or IV (handles a limited selection of easily
managed objects).
2. Assessment of spasticity and range of motion:
To aid identification of appropriate muscles to be
treated with BoNT-A, spasticity in the upper and
lower limbs will be assessed with the Modified
Tardieu Scale (MTS) [48] and passive resistance of
the muscle with the Modified Ashworth Scale
(MAS) [49]. Passive range of motion of the limbs
will also be recorded. Muscles that are assessed to
have spasticity and appear to impact on identified
goals will be selected for injection. For example, if
extending the arms for dressing is identified as being
an area of difficulty for carers and the elbow flexors
are determined to be spastic, injections to biceps
brachii, brachialis and/or brachioradialis will be
planned. If lower limb dressing is hindered by
difficulty abducting the legs due to spasticity in the
hip adductors and medial hamstrings, injections to
these muscle groups will be performed.
3. Primary and Secondary Outcome Measures:
The primary outcome measure for this study is
change in parent ratings in identified areas ofconcerns for their child’s care and comfort, using
the Canadian Occupational Performance Measure
(COPM). Secondary measures include measures of
pain, ease of care, health status and quality of life.
To maximise reliability in the study, the same
person (the child’s primary caregiver) will be
responsible for completing the measures at each
assessment point.
a) Ease of Care
The primary outcome to assess ease of care and
comfort will be the Canadian Occupational
Performance Measure (COPM) [44]. The COPM is
a client-centered tool which aims to identify
concerns and issues of occupational performance,
incorporating self-maintenance (activities of daily
living, functional mobility, and community
management), productivity (participation at school
and in play) and leisure (quiet recreation, active
recreation and socialization). The COPM allows for
consistent measurement of a broad range of issues
unique to children and families that may not be
detected by standardized measures. This is
important as our sample will be heterogeneous in
terms of motor presentation (GMFCS IV and V),
degree of spasticity and contracture, and age (2-
16 years). The COPM has been used previously in
studies of efficacy of intramuscular BoNT-A
injections [13,15,35].
The COPM is a semi-structured interview
conducted with parents, by a clinician skilled in its
use. The modifications for using the COPM with a
paediatric sample suggested by Cusick et al [76] will
be applied in this study. For each participant, a
parent will be asked to report areas of concern for
their child’s care and comfort in the domains of self-
maintenance, productivity (school/play) and leisure.
Parents will then select a minimum of two of the
most important areas that impact upon burden of
care or discomfort and rate their concerns on two 1-
10 ordinal scales (performance and satisfaction).
Follow-up assessments require that parents re-rate
their concerns according to performance and
satisfaction, without reference to their original
ratings, so as not to bias their responses [77]. A
two point change in total performance or
satisfaction has been shown to indicate clinical
significance [44]. The COPM has been shown to
be valid [44,78,79] and reliable [80] with high
test/re-test reliability (Spearman’s Rho 0.89 for
performance scores, 0.88 for satisfaction scores)
[81]. The COPM takes approximately 20 minutes
to complete.
In addition to parent report of unique individual
concerns, ease of care and comfort will be assessed
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Questionnaire (CCHQ) [82]. The CCHQ uses a
seven point scale and will be used to measure
specific aspects of ease of care and comfort in the
areas of personal care, positioning/transferring,
comfort and interaction/communication. The
CCHQ has been designed for use with children with
severe disabilities associated with hypertonicity of
cerebral origin. Content validity has been established
and responsiveness to change has been shown for
intrathecal baclofen treatment with children with
severe CP [82]. It takes approximately 10 minutes to
complete.
b) Quality of life
Quality of life is a broad term encompassing well-
being across a variety of domains including physical
and psychological status, function, social interactions
and economic status [83]. Quality of life is
important to measure in clinical studies with
children with CP, as the relationship between clinical
indicators of disability and the subjective experience
of disability is not clear [83].
We will measure quality of life pre and post
intervention with the Children with Cerebral Palsy
Quality of Life Questionnaire (CP QoL–Child) [84].
The CP QoL-Child is a condition specific quality of
life tool designed for use for children with CP aged
4-12 years. Both a parent proxy version and a child
self- report version are available. The parent version
will be used for this study. Domains include: Social
Wellbeing and Acceptance; Feelings about
Functioning; Participation and Physical Health;
Emotional Wellbeing, Access to Services; Pain and
Impact of Disability and Family Health. Internal
consistency ranges from 0.74-0.92 [85]. Test re-test
reliability ranges from 0.76-0.89 [85]. The CP QoL-
Child takes approximately 10-15 minutes to
complete. A recent systematic review of CP-specific
quality of life measures concluded that the CP QoL-
Child had the strongest foundation in the theoretical
basis of quality of life, measuring quality of life
across broad domains [86].
c) Health status
Children with non-ambulant CP are at risk of
multiple health related problems [34] which lead to
activity restrictions. In this study, health status will
be measured using the Caregiver Priorities and Child
Health Index of Life with Disabilities (CPCHILD©)
Questionnaire [87], which was developed to measure
health status and wellbeing of children with severe
CP, from the perspective of caregivers. The tool
consists of 37 items over 6 domains: Personal Care;
Positioning, Transferring and Mobility; Comfort and
Emotions; Communication and Social InteractionHealth; & Overall Quality of Life. Ordinal scales are
used within each domain. Developed as an
evaluative tool, initial reports of its psychometric
properties suggest that it is a valid measure of
parent’s perceptions of their child’s health status,
functional limitations and well-being, and test re-test
reliability of the total questionnaire score was high
(ICC 0.97 (0.95-0.99)) [87]. To date, the CPCHILD
has not been used in BoNT-A outcome studies. It
takes approximately 15 minutes to complete.
d) Pain
Injections of BoNT-A may reduce pain in children
with non-ambulant CP [20]. We will assess pain
using the Paediatric Pain Profile (PPP) [22]. The
PPP is a 20 item behaviour rating scale designed
to assess pain in children with non-ambulant CP
and other severe neurological impairments.
Behaviours include changes in facial expressions,
vocal sounds, posture and movements, daily
routines and mood. The tool has established
validity for use with children with neurological
conditions [88]. Intra-rater reliability for total
scores (ICC= 0.90) is reported to be better than
inter-rater reliability (ICC= 0.62 - 0.83) [88].Analyses
Cycle I- efficacy of BoNT-A injections for improving ease of
care and comfort
Analysis will follow standard principles for RCTs, using
two-group comparisons on all participants on an
intention to treat basis. Data from each outcome meas-
ure will be summarized for each group and descriptive
statistics (frequencies, means, medians, 95% confidence
intervals) calculated dependent on data distribution. We
anticipate that groups will be similar on baseline mea-
sures. The primary comparison for hypothesis one at
4 weeks will be the COPM performance and satisfaction
scores. Generalised estimating equations (GEEs) will be
used to compare treatment groups at follow-up, with
time (0, 4 and 16 weeks) and study group, as well as a
time by group interaction as covariables [89]. We will
use the Gaussian family, identity link, and an unstruc-
tured correlation structure. Secondary analyses will com-
pare the outcomes between groups for ease of care,
quality of life, pain and health status using GEEs as out-
lined above (STATA 11).Cycle I: safety of BoNT-A injections compared with sham
Two Chi-squared tests of independence will be con-
ducted to assess the relationship between treatment and
sham and all adverse events vs. moderate and serious
events. The continuity correction chi-square will enable
analysis by 2 × 2 tables using Fisher’s exact test.
Thorley et al. BMC Pediatrics 2012, 12:120 Page 10 of 12
http://www.biomedcentral.com/1471-2431/12/120Cycle II: efficacy of repeated episodes of BoNT-A injections
vs. single episode
The primary outcome measure for cycle II will be the
COPM administered at 4 weeks post injections. The
secondary outcome measures will be the same as
cycle I (CPCHILD, CP QoL-Child, CCHQ and PPP).
Generalised estimating equations (GEEs) will be used
to compare treatment groups at follow-up, with time
(0, 16 weeks and 10 months) and study group, as well
as a time by group interaction as covariables. We will
use the Gaussian family, identity link, and an unstruc-
tured correlation structure. Secondary analyses will
compare the outcomes between groups for ease of
care, quality of life, pain and health status using GEEs
as outlined above (STATA 11).Cycle II: safety of repeated episodes of BoNT-A injections vs.
single episode
Adverse events in cycle II will be collected as per cycle I.
Rates of adverse events will compared between groups
using Poisson regression.Discussion
This paper presents the background and design for a
double blind, randomized controlled trial. This study
is the first to rigorously examine the efficacy and
safety of BoNT-A in addition to standard therapy to
improve care and comfort for children with non-
ambulant CP using a strong study design to minimize
bias. Outcomes will be measured using valid and reli-
able measurement tools and the double blind sham
study design will further strengthen the attribution of
effects and monitoring of safety.Competing interests
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